Results 11 to 20 of about 21,815 (182)
TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer.
In treating patients with castration resistant prostate cancer (CRPC), enzalutamide, the second-generation androgen receptor (AR) antagonist, is an accepted standard of care.
Geun Taek Lee +7 more
doaj +2 more sources
Relugolix Plus Enzalutamide For Metastatic Hormone-Sensitive Prostate Cancer: A Case Report [PDF]
Alastair Thomson,1 Lucinda Gunn,1 Deborah Victor,1 Ellis Adamson,1 Kashyap Thakrar2 1Oncology Department, Sunrise Centre, Royal Cornwall Hospital, Truro, Cornwall, UK; 2Accord-UK Ltd, Barnstaple, Devon, UKCorrespondence: Alastair Thomson, Oncology ...
Thomson A +4 more
doaj +1 more source
Identification of selective SWI/SNF dependencies in enzalutamide-resistant prostate cancer [PDF]
Enzalutamide is a potent second-generation antiandrogen commonly used to treat hormone-sensitive and castration-resistant prostate cancer (CRPC) patients. While initially effective, the disease almost always develops resistance.
Bengul Gokbayrak +17 more
doaj +2 more sources
Mechanism-Informed Language Modeling and Oxygenated 3D Screening Identify Berberine-Enzalutamide Synergy in Prostate Cancer Models. [PDF]
By integrating knowledge‐augmented artificial intelligence with an oxygen‐supplemented 3D screening platform, a synergistic interaction between berberine and enzalutamide is identified. The framework integrates compound mechanisms of action with disease‐relevant signaling context to prioritize candidate combinations and generate testable pathway‐based ...
Lo CH +15 more
europepmc +2 more sources
Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study. [PDF]
Background While the cardiovascular risks of androgen receptor pathway inhibitors have been studied, they were seldom compared directly. This study compares the risks of major adverse cardiovascular events (MACE) between enzalutamide and abiraterone ...
Jeremy Man Ho Hui +12 more
core +3 more sources
The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells
Enzalutamide is a second-generation anti-androgen which has shown increased survival in patients with metastatic prostate cancer. However, some patients do not respond to this therapy or will develop resistance to treatment over time.
Rebecka Hellsten +4 more
doaj +1 more source
Background The standard treatment for non-metastatic castration sensitive prostate cancer (nmCSPC) is androgen deprivation therapy (ADT) or surveillance. This study evaluated the potential synergy of immunotherapy and enzalutamide (without ADT) in nmCSPC.
Harpreet Singh +14 more
doaj +1 more source
BackgroundAbiraterone and enzalutamide are widely used as first-line treatment for metastatic castration-resistant prostate cancer (mCRPC); however, their efficacy in mCRPC has been inconsistently demonstrated in other outcome studies from real-world ...
Pei-Yu Li +6 more
doaj +1 more source
Efficacy of enzalutamide treatment based on initial dose of enzalutamide.
Efficacy of enzalutamide treatment based on initial dose of enzalutamide.
Jun Miki (11512692) +10 more
core +1 more source
Drug‐drug interaction (DDI) is an important consideration for clinical decision making in prostate cancer treatment. The objective of this study was to evaluate the effect of enzalutamide, an oral androgen receptor inhibitor, on the pharmacokinetics (PK)
Srinivasu Poondru +8 more
doaj +1 more source

